Coronavirus Live Count Map India
remove_red_eye 532 Views
COVID-19 Vaccine Updates
#Emergency Medicine #Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine
Treatment of severe COVID-19 patients with tocilizumab along with standard care appears to be not superior to standard care alone for improving clinical outcomes at 15 days, suggested a study published in the BMJ. The study was stopped early as there were increased number of deaths among the patients who received the drug.
An increased number of deaths at 15 days was noted in severe COVID-19 patients who were administered tocilizumab, which contradicts previous observational studies that indicated a benefit of the drug. Scientists, including those from Universidade Federal de Sao Paulo in Brazil, have stated that these contradictory results must be evaluated in future studies. They added that tocilizumab blocks interleukin-6 which can go into overdrive in some COVID-19 patients… (HT – PTI, January 21, 2021)
To comment on this article,
create a free account.
Already registered?
.jpg)
Tocilzumab by itself suppress the severe inflammatory response which is dangerous immunogenic response in severe infection with sars covid 19 pandemic infections took.administration is advised in moderate to severe cases of sars covid 19 pandemic infections with severe respiratory abd cardiac involvement along with my curative treatments therapy for sars covid 19 infections including either iv remedesivir or iv favipiravir for total duration of 14 days with twice daily doses after patients RT PCR BLOOD TEST IS POS ITIVE FOR SARS COVID 19 PANDEMIC INFECTIONS YEAR 2020,2021 THEREAFTER ALSO. REGARDS BRAHMIN DR MAHADEVI RANI DR SUNITA SAMPATRAO MORE DEV MAHADEV